| pubmed-article:20805033 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20805033 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:20805033 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
| pubmed-article:20805033 | lifeskim:mentions | umls-concept:C0376358 | lld:lifeskim |
| pubmed-article:20805033 | lifeskim:mentions | umls-concept:C0020792 | lld:lifeskim |
| pubmed-article:20805033 | lifeskim:mentions | umls-concept:C0085153 | lld:lifeskim |
| pubmed-article:20805033 | lifeskim:mentions | umls-concept:C1516463 | lld:lifeskim |
| pubmed-article:20805033 | lifeskim:mentions | umls-concept:C0871161 | lld:lifeskim |
| pubmed-article:20805033 | pubmed:issue | 19 | lld:pubmed |
| pubmed-article:20805033 | pubmed:dateCreated | 2010-9-20 | lld:pubmed |
| pubmed-article:20805033 | pubmed:abstractText | The process of cancer development consists of three sequential stages termed initiation, promotion, and progression. Oxidative stress damages DNA and introduces mutations into oncogenes or tumor suppressor genes, thus contributing to cancer development. Cancer chemoprevention is defined to prevent or delay the development of cancer by the use of natural or synthetic substances. In the present study, we synthesized a series of organoselenium compounds and evaluated their possible chemopreventive properties in human prostate cancer LNCaP cells. Among 42 organoselenium compounds tested, two compounds, 3-selena-1-dethiacephem 13 and 3-selena-1-dethiacephem 14 strongly activated the Nrf2/ARE (antioxidant response element) signaling and thus markedly increased expression of heme oxygenase-1 (HO-1), a phase II antioxidant enzyme. Translocation of Nrf2 to the nucleus preceded HO-1 protein induction by two compounds. The intracellular ROS level was strongly reduced immediately after treatment with these compounds, showing that they are potent antioxidants. Finally, both compounds inhibited cell growth via cell cycle arrest. Our findings suggest that compounds 13 and 14 could not only attenuate oxidative stress through Nrf2/ARE activation and direct ROS scavenging but also inhibit cell growth. Thus, these compounds possess the potential as pharmacological agents for chemoprevention of human prostate cancer. | lld:pubmed |
| pubmed-article:20805033 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20805033 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20805033 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20805033 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20805033 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20805033 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20805033 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20805033 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20805033 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20805033 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20805033 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20805033 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:20805033 | pubmed:issn | 1464-3391 | lld:pubmed |
| pubmed-article:20805033 | pubmed:author | pubmed-author:DeguchiTakash... | lld:pubmed |
| pubmed-article:20805033 | pubmed:author | pubmed-author:KoketsuMamoru... | lld:pubmed |
| pubmed-article:20805033 | pubmed:author | pubmed-author:ItoMasafumiM | lld:pubmed |
| pubmed-article:20805033 | pubmed:author | pubmed-author:NozawaYoshino... | lld:pubmed |
| pubmed-article:20805033 | pubmed:author | pubmed-author:ItohTomohiroT | lld:pubmed |
| pubmed-article:20805033 | pubmed:author | pubmed-author:FujitaYasunor... | lld:pubmed |
| pubmed-article:20805033 | pubmed:author | pubmed-author:NakaneKeitaK | lld:pubmed |
| pubmed-article:20805033 | pubmed:author | pubmed-author:GarudDinesh... | lld:pubmed |
| pubmed-article:20805033 | pubmed:author | pubmed-author:HamadaNanakoN | lld:pubmed |
| pubmed-article:20805033 | pubmed:author | pubmed-author:TerazawaRiyak... | lld:pubmed |
| pubmed-article:20805033 | pubmed:copyrightInfo | Copyright © 2010 Elsevier Ltd. All rights reserved. | lld:pubmed |
| pubmed-article:20805033 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20805033 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:20805033 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:20805033 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20805033 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20805033 | pubmed:pagination | 7001-8 | lld:pubmed |
| pubmed-article:20805033 | pubmed:meshHeading | pubmed-meshheading:20805033... | lld:pubmed |
| pubmed-article:20805033 | pubmed:meshHeading | pubmed-meshheading:20805033... | lld:pubmed |
| pubmed-article:20805033 | pubmed:meshHeading | pubmed-meshheading:20805033... | lld:pubmed |
| pubmed-article:20805033 | pubmed:meshHeading | pubmed-meshheading:20805033... | lld:pubmed |
| pubmed-article:20805033 | pubmed:meshHeading | pubmed-meshheading:20805033... | lld:pubmed |
| pubmed-article:20805033 | pubmed:meshHeading | pubmed-meshheading:20805033... | lld:pubmed |
| pubmed-article:20805033 | pubmed:meshHeading | pubmed-meshheading:20805033... | lld:pubmed |
| pubmed-article:20805033 | pubmed:meshHeading | pubmed-meshheading:20805033... | lld:pubmed |
| pubmed-article:20805033 | pubmed:meshHeading | pubmed-meshheading:20805033... | lld:pubmed |
| pubmed-article:20805033 | pubmed:meshHeading | pubmed-meshheading:20805033... | lld:pubmed |
| pubmed-article:20805033 | pubmed:meshHeading | pubmed-meshheading:20805033... | lld:pubmed |
| pubmed-article:20805033 | pubmed:meshHeading | pubmed-meshheading:20805033... | lld:pubmed |
| pubmed-article:20805033 | pubmed:meshHeading | pubmed-meshheading:20805033... | lld:pubmed |
| pubmed-article:20805033 | pubmed:meshHeading | pubmed-meshheading:20805033... | lld:pubmed |
| pubmed-article:20805033 | pubmed:meshHeading | pubmed-meshheading:20805033... | lld:pubmed |
| pubmed-article:20805033 | pubmed:meshHeading | pubmed-meshheading:20805033... | lld:pubmed |
| pubmed-article:20805033 | pubmed:meshHeading | pubmed-meshheading:20805033... | lld:pubmed |
| pubmed-article:20805033 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20805033 | pubmed:articleTitle | Identification of organoselenium compounds that possess chemopreventive properties in human prostate cancer LNCaP cells. | lld:pubmed |
| pubmed-article:20805033 | pubmed:affiliation | Department of Longevity and Aging Research, Gifu International Institute of Biotechnology, 1-1 Naka-fudogaoka, Kakamigahara, Gifu 504-0838, Japan. | lld:pubmed |
| pubmed-article:20805033 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20805033 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:20805033 | lld:chembl |
